474 related articles for article (PubMed ID: 30818416)
1. Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes.
Moncharmont P; Quittançon E; Barday G; Benamara A;
Vox Sang; 2019 May; 114(4):349-354. PubMed ID: 30818416
[TBL] [Abstract][Full Text] [Related]
2. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Sanz C; Nomdedeu M; Belkaid M; Martinez I; Nomdedeu B; Pereira A
Transfusion; 2013 Apr; 53(4):710-5. PubMed ID: 22845746
[TBL] [Abstract][Full Text] [Related]
3. Adverse transfusion reactions in recipients transfused in out-of-hospital.
Moncharmont P; Barday G; Odent-Malaure H; Benamara H;
Transfus Clin Biol; 2018 May; 25(2):105-108. PubMed ID: 29555413
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes.
Lin Y; Saskin A; Wells RA; Lenis M; Mamedov A; Callum J; Buckstein R
Vox Sang; 2017 Jan; 112(1):79-86. PubMed ID: 28097704
[TBL] [Abstract][Full Text] [Related]
5. Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
Leisch M; Weiss L; Lindlbauer N; Jungbauer C; Egle A; Rohde E; Greil R; Grabmer C; Pleyer L
Leuk Res; 2017 Aug; 59():12-19. PubMed ID: 28535394
[TBL] [Abstract][Full Text] [Related]
6. Impact of Red Blood Cell Antigen Matching on Alloimmunization and Transfusion Complications in Patients with Sickle Cell Disease: A Systematic Review.
Fasano RM; Meyer EK; Branscomb J; White MS; Gibson RW; Eckman JR
Transfus Med Rev; 2019 Jan; 33(1):12-23. PubMed ID: 30122266
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia.
Killick SB; Win N; Marsh JC; Kaye T; Yandle A; Humphries C; Knowles SM; Gordon-Smith EC
Br J Haematol; 1997 Jun; 97(3):677-84. PubMed ID: 9207422
[TBL] [Abstract][Full Text] [Related]
8. Acquired red blood cell alloantibodies in transfused patients of 80 years or over: a 2008-2013 national haemovigilance survey.
Moncharmont P; Barday G; Py JY; Meyer F;
Blood Transfus; 2017 May; 15(3):254-258. PubMed ID: 27416567
[TBL] [Abstract][Full Text] [Related]
9. Haemolytic transfusion reactions caused by non-ABO red cell antibodies reported to the Norwegian Haemovigilance System 2004-2020.
Espinosa A; Steinsvåg CT; Flesland Ø
Vox Sang; 2024 May; 119(5):483-489. PubMed ID: 38373854
[TBL] [Abstract][Full Text] [Related]
10. Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome.
Singhal D; Kutyna MM; Chhetri R; Wee LYA; Hague S; Nath L; Nath SV; Sinha R; Wickham N; Lewis ID; Ross DM; Bardy PG; To LB; Reynolds J; Wood EM; Roxby DJ; Hiwase DK
Haematologica; 2017 Dec; 102(12):2021-2029. PubMed ID: 28983058
[TBL] [Abstract][Full Text] [Related]
11. Red blood cell transfusion in myelodysplastic syndromes: A systematic review.
Kaka S; Jahangirnia A; Beauregard N; Davis A; Tinmouth A; Chin-Yee N
Transfus Med; 2022 Feb; 32(1):3-23. PubMed ID: 34927286
[TBL] [Abstract][Full Text] [Related]
12. Transfusion Support of Patients with Myelodysplastic Syndromes.
Guarente J; Tormey C
Clin Lab Med; 2023 Dec; 43(4):669-683. PubMed ID: 37865510
[TBL] [Abstract][Full Text] [Related]
13. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
[TBL] [Abstract][Full Text] [Related]
14. Comparing transfusion reaction risks for various plasma products - an analysis of 7 years of ISTARE haemovigilance data.
Saadah NH; van der Bom JG; Wiersum-Osselton JC; Richardson C; Middelburg RA; Politis C; Renaudier P; Robillard P; Schipperus MR
Br J Haematol; 2018 Mar; 180(5):727-734. PubMed ID: 29318576
[TBL] [Abstract][Full Text] [Related]
15. Haemovigilance of reactions associated with red blood cell transfusion: comparison across 17 Countries.
Rogers MA; Rohde JM; Blumberg N
Vox Sang; 2016 Apr; 110(3):266-77. PubMed ID: 26689441
[TBL] [Abstract][Full Text] [Related]
16. Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome.
Ortiz S; Orero MT; Javier K; Villegas C; Luna I; Pérez P; Roig M; López M; Costa S; Carbonell F; Collado R; Ivars D; Linares M
Blood Transfus; 2017 Sep; 15(5):472-477. PubMed ID: 27416573
[TBL] [Abstract][Full Text] [Related]
17. [Allergic adverse transfusion reactions in paediatrics, a 3-year study].
Moncharmont P; Meyer F
Transfus Clin Biol; 2013 Dec; 20(5-6):455-7. PubMed ID: 24269196
[TBL] [Abstract][Full Text] [Related]
18. [Automated screening for transfusionnal hemochromatosis].
Costello R; Huret G; Sappa E; Bergoin-Costello V
Transfus Clin Biol; 2012 Apr; 19(2):57-9. PubMed ID: 22503459
[TBL] [Abstract][Full Text] [Related]
19. [Anemia with aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes].
Passweg JR
Ther Umsch; 2010 May; 67(5):251-5. PubMed ID: 20509122
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
